SCHEMBL14879484

SCHEMBL14879484

O=Cc1ccc(-c2ccc(Cl)cc2)c(F)c1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.44
XDH P47989 1/20 0.41
HSD17B10 Q99714 1/20 0.40
ERN1 O75460 4/20 0.37
MAPT P10636 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
POLB P06746 1/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
KCNJ1 P48048 1/20 0.36
AHR P35869 1/20 0.34
GAA P10253 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PTGS2 P35354 2/20 0.33
PTGS1 P23219 1/20 0.33
NR4A2 P43354 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL505506 0.84 PTGS1 (0.42) ERN1MAPTKDM4EALDH1A1POLB
SCHEMBL2360182 0.83 ERN1 (0.44) TDP1XDHHSD17B10ERN1KDM4E
SCHEMBL2599745 0.80 KMT2A (0.42) TDP1ERN1ALDH1A1POLBLMNA
SCHEMBL8054629 0.78 MDM2 (0.46) TDP1XDHHSD17B10ERN1MAPT
SCHEMBL8015322 0.77 NR4A2 (0.40) HSD17B10SMN1; SMN2LMNAAHRPTGS2
SCHEMBL21774209 0.76 QPCT (0.41) TDP1XDHERN1KCNJ1
SCHEMBL19153597 0.76 TDP1 (0.57) TDP1XDHHSD17B10ERN1MAPT
SCHEMBL28854793 0.76 XDH (0.62) TDP1XDHHSD17B10ERN1MAPT
SCHEMBL31306389 0.76 TDP1 (0.47) TDP1ERN1KDM4EALDH1A1LMNA
SCHEMBL31306390 0.76 TDP1 (0.47) TDP1ERN1KDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2768491-B1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS INC (US) 2016-12-21 EP disclosed
US-9266908-B2 Inhibitors of arginase and their therapeutic applications MARS, INCORPORATED (US) 2016-02-23 US disclosed
US-20140343019-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2014-11-20 US disclosed
EP-2768491-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS Mars, Incorporated (US) 2014-08-27 EP disclosed
WO-2013059437-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED (US) 2013-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343019-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS ARG1, ARG2, PRMT1 TDP1 743/4885XDH 368/4885HSD17B10 2679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.